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The papers in this Value in Health Special Issue document the
process of health technology assessment (HTA) in various coun-
tries very well and the opening and closing editorials draw impor-
tant lessons from these that should help the development of HTA
and related policy setting in countries with less well-developed
systems. Two themes seem to weave throughout the issue: that
a full HTA should include consideration of efﬁciency (“cost-
effectiveness”) and that despite methodological developments,
we have not been very successful at persuading stakeholders
outside the HTA community to see the value in our activities and
adopt our procedures wholeheartedly. Perhaps, these two are
closely related—our audiences are reluctant to embrace our
approach because they reject at some fundamental level our focus
on efﬁciency.
Our current focus on efﬁciency stems from the two ideas that
are said to form the very rationale for health economic evalua-
tion: that the goal of the health-care system is “maximizing
health” and that this must be accomplished with limited
resources. It seems obvious that if this is the problem, then the
solution must involve assessing efﬁciency—how much health one
buys per monetary unit—and that this requires a universal unit of
health in order to have a common measure that allows compari-
sons across interventions. As presented didactically, this appears
to work: set the budget, start with the most efﬁcient intervention,
and continue adding others in order of decreasing efﬁciency until
the budget is spent. The trouble is that this idea fails entirely,
from practice, to concepts, to fundamentals.
The practical failures are many. None of our health-care
systems are open to designing from scratch—we cannot follow
the didactic prescription. Instead, we have an existing set of
interventions that are covered, most of which have never been
evaluated. We have no idea what their efﬁciency is, so we do not
know what the lowest covered efﬁciency is. When faced with
assessing a new intervention for coverage within the budget, we
can establish its efﬁciency but it is not clear what the decision-
makers are supposed to do with that information. So, we invent
a threshold efﬁciency and propose that the new intervention’s
efﬁciency be compared with it: if it is worse, do not cover;
otherwise, go ahead and reimburse. But that, of course, does not
respect the budget limit—on the contrary, it forces an increase as
no “inefﬁcient” interventions are identiﬁed and removed.
Even if we did take pains to identify less efﬁcient interven-
tions, basing the trade-off on efﬁciency would still not be very
helpful as the new intervention might command a much larger
share of the budget than the one proposed for withdrawal. This
would still be the case even if we made an effort to establish what
the insured citizens think the minimum efﬁciency should be
(assuming such a question can be meaningfully asked and
answered). The concept of comparing efﬁciency as a means to
making coverage decisions for new interventions within a par-
ticular budget does not work because it does not address the
trade-offs that are required.
What if we could redesign the system, perhaps in stages, so
that eventually we would be covering only the most efﬁcient
interventions up to the budget limit? Would such a system
achieve what the insured citizens want? That depends on whether
citizens generally want their health-care system to yield the
highest aggregate health regardless of how that total is obtained.
This is clearly not the case as it matters to people what illnesses
are treated. Health gained by removing minor complaints is not
as valuable as that obtained by dealing with severe or life-
threatening diseases. No one would accept to prioritize headache
treatment over cancer removal no matter how much more efﬁ-
cient the former is or how much greater its total health gain
might be. The fundamental idea that we should maximize aggre-
gate health is not tenable.
Instead, what our health-care systems need to do with their
limited budgets is maximize value and no dimensions of health
(e.g., the quality-adjusted life-year) will be a good measure of
value because people consider other aspects in their evaluations.
It is difﬁcult, of course, to assess value, but choosing to measure
something else because it is easier to do will not produce HTAs
that are persuasive to the stakeholders.
So, is there a role for efﬁciency? There is, but it is much more
limited. Efﬁciency is important when purchasing a particular
beneﬁt. If one wants to cover treatments for headache, then it is
desirable to purchase the most relief with a given budget and this
requires that efﬁciency be estimated in these terms. More efﬁcient
pain relievers should be preferred for coverage. Whether one
should cover headache treatments, or to what extent, is a whole
other matter, and is not informed much by efﬁciency.
In my view, then, HTA will fail to gain traction with stake-
holders so long as overall efﬁciency is viewed as its ultimate
output. Providing competent review and summary of the evi-
dence, as well as estimates of the possible health impact of a
proffered intervention together with its budgetary implications,
should be very useful to decision-makers. In therapeutic areas
with multiple available interventions, estimation of their efﬁ-
ciency at providing the speciﬁc beneﬁts in that area should also
be useful. If we want our HTAs to go beyond that without
leaving our audiences behind, we will need to get into the much
more difﬁcult business of weighing the values our citizens place
on different health beneﬁts. We must back out of the dead end
that is pursuing overall efﬁciency.
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